MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Sonoma Pharmaceuticals Net Debt 2011-2026 | SNOA
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Sonoma Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.29 M | -2.84 M | -3.4 M | -6.84 M | -2.67 M | -2.21 M | -3.36 M | -9.8 M | -17.3 M | -7.36 M | -6.05 M | -5.33 M | -5.96 M | -112 K | -1.83 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -112 K | -17.3 M | -5.36 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Drug manufacturers industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
-11.2 M | - | - | $ 142 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-22.5 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-11.1 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
193 M | $ 1.2 | 1.27 % | $ 129 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
-6.59 M | - | 7.5 % | $ 6.35 M | USA |
 |
Cronos Group
CRON
|
-1.07 B | $ 2.68 | -0.56 % | $ 1.42 B | Canada |
 |
Agile Therapeutics
AGRX
|
-676 K | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
4.58 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
-10.4 M | - | - | $ 50.1 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-931 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Eagle Pharmaceuticals
EGRX
|
2.43 M | - | -39.89 % | $ 27.7 M | USA |
 |
HEXO Corp.
HEXO
|
-150 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Endo International plc
ENDP
|
7.37 B | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-2.96 M | - | - | $ 36.6 M | USA |
 |
Emergent BioSolutions
EBS
|
338 M | $ 13.92 | 5.86 % | $ 713 M | USA |
 |
OrganiGram Holdings
OGI
|
90.7 M | $ 1.69 | 0.9 % | $ 402 M | Canada |
 |
Athenex
ATNX
|
-28.3 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-49.7 M | $ 21.48 | -0.12 % | $ 2.04 B |  France |
 |
Evolus
EOLS
|
36.3 M | $ 5.72 | -3.3 % | $ 355 M | USA |
 |
Harrow Health
HROW
|
173 M | $ 50.79 | -5.07 % | $ 1.66 B | USA |
 |
China Pharma Holdings
CPHI
|
-4.73 M | $ 1.38 | 9.13 % | $ 24.1 M |  China |
 |
Sundial Growers
SNDL
|
-28.4 M | $ 1.66 | -1.19 % | $ 3.37 M | Canada |
 |
Jupiter Wellness
JUPW
|
-21.7 K | - | - | $ 33.6 M | USA |
 |
Bausch Health Companies
BHC
|
21.1 B | $ 7.9 | 3.41 % | $ 2.88 B | Canada |
 |
Lannett Company
LCI
|
529 M | - | 1.15 % | $ 7.11 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-12.7 M | $ 5.14 | 8.9 % | $ 72.3 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-146 M | - | - | $ 193 M | Canada |
 |
Organogenesis Holdings
ORGO
|
-131 M | $ 4.32 | -0.92 % | $ 569 M | USA |
 |
Aurora Cannabis
ACB
|
285 M | $ 4.23 | -0.25 % | $ 86.3 M | Canada |
 |
Pacira BioSciences
PCRX
|
317 M | $ 26.13 | 3.24 % | $ 1.21 B | USA |
 |
PetIQ
PETQ
|
329 M | - | 1.64 % | $ 400 M | USA |
 |
Recro Pharma
REPH
|
-6.65 M | - | -4.76 % | $ 65.3 M | USA |
 |
Perrigo Company plc
PRGO
|
3.05 B | $ 14.7 | -0.47 % | $ 2.02 B | USA |
 |
ProPhase Labs
PRPH
|
-6.41 M | - | - | $ 5.07 M | USA |
 |
Rockwell Medical
RMTI
|
691 K | $ 0.95 | 2.85 % | $ 22.2 M | USA |
 |
Radius Health
RDUS
|
-111 M | - | - | $ 1.42 B | USA |
 |
Relmada Therapeutics
RLMD
|
-2.5 M | $ 4.3 | 5.39 % | $ 129 M | USA |
 |
OptiNose
OPTN
|
-72.2 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
-34 M | $ 9.35 | -1.86 % | $ 664 M | USA |
 |
PLx Pharma
PLXP
|
-21.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
-70.9 M | $ 5.58 | 1.64 % | $ 228 M | USA |
 |
SCYNEXIS
SCYX
|
-31.1 M | $ 0.64 | -0.12 % | $ 30.6 M | USA |
 |
Tricida
TCDA
|
-7.08 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
14.4 M | $ 8.95 | -3.35 % | $ 5.53 B | Canada |
 |
Veru
VERU
|
-20.9 M | $ 2.34 | 0.43 % | $ 316 M | USA |
 |
TherapeuticsMD
TXMD
|
3.68 M | $ 2.0 | -2.0 % | $ 20.9 M | USA |
 |
Viatris
VTRS
|
16.8 B | $ 12.42 | 0.12 % | $ 15.1 B | USA |
 |
cbdMD
YCBD
|
-521 K | $ 1.11 | -3.91 % | $ 4.79 M | USA |
 |
Zomedica Corp.
ZOM
|
-10.2 M | - | -0.21 % | $ 98 M | USA |